Breast Cancer Clinical Trial

MRI Characterization of Mammographically Detected DCIS

Summary

This is a single institution, prospective observational clinical trial for women with mammographically identified calcifications that may represent ductal carcinoma in situ (DCIS).

The purpose of this study is to determine whether quantitative, multiparametric breast MRI performed prior to surgical resection can biologically characterize this common pre-invasive malignancy, ductal carcinoma in situ (DCIS), which typically presents in asymptomatic women as suspicious calcifications on mammography.

View Full Description

Full Description

The investigators will assess whether MRI signatures can determine which calcifications identified prior to surgical resection actually harbor DCIS, and whether these imaging features correlate with pathologic markers of proliferation (Ki-67) and inflammation (cox-2) within DCIS lesions.

The investigators will also explore whether quantitative MRI features in the peri-tumoral region correlate with prognostic microenvironment markers of inflammation (TNFα) and angiogenesis (VEGF). Finally, investigators will assess whether a multivariate model using these markers can accurately predict risk of recurrence based on a multi-gene assay (Oncotype DX DCIS score).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

[Cohort A] Women aged 18 or older with suspicious calcifications identified on mammography without an associated mass
[Cohort B] Women aged 18 or older with recent biopsy-proven DCIS with residual calcifications present on mammogram after biopsy

Exclusion Criteria for Both Cohorts:

Patients with prior history of breast cancer in the ipsilateral breast
Patients with a newly diagnosed breast cancer in the contralateral breast
Contra-indication to contrast-enhanced breast MRI (e.g. renal insufficiency with GFR<60, contrast allergy, incompatible metal)
Patients who currently are undergoing chemoprevention therapy (e.g. aromatase inhibitors or selective estrogen receptor modulators)
Women who are pregnant

Study is for people with:

Breast Cancer

Estimated Enrollment:

150

Study ID:

NCT03495011

Recruitment Status:

Recruiting

Sponsor:

University of Washington

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Fred Hutch/University of Washington Cancer Consortium
Seattle Washington, 98109, United States More Info
Research Coordinator
Contact
206-606-6714
[email protected]
Habib Rahbar
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

150

Study ID:

NCT03495011

Recruitment Status:

Recruiting

Sponsor:


University of Washington

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.